WCN26-5800 VISOR: AN ONGOING REPEAT-BIOPSY CLINICAL TRIAL ASSESSING CHANGES IN KIDNEY HISTOLOGY IN PEOPLE WITH IgA NEPHROPATHY TREATED WITH SIBEPRENLIMAB

compared to late LN (12.5% ,p=0.04).Class IV nephritis predominated in both groups (early: 69.3%; delayed: 61.0%; p=0.44).Immunosuppressive regimens were comparable between the groups, though the use of cyclophosphamide was higher in early nephritis .There was no significant difference in the incidence of ESRD (20.4% in early vs. 31.7% in late, p=0.23) or mortality (12.2% vs. 19.5%,p=0.38).The mean time to remission was also similar (8.59 vs. 8.63 months; p=0.98).Early Late P value Median age at LN diagnosis 23.5 29 0.08